Laboratory Co. of America Holdings (NYSE:LH) Position Decreased by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its holdings in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 7.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,353 shares of the medical research company's stock after selling 4,582 shares during the quarter. Victory Capital Management Inc. owned about 0.07% of Laboratory Co. of America worth $12,370,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of LH. Diamond Hill Capital Management Inc. lifted its stake in shares of Laboratory Co. of America by 1.5% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,978,686 shares of the medical research company's stock valued at $442,197,000 after purchasing an additional 29,046 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Laboratory Co. of America by 16.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,865,460 shares of the medical research company's stock valued at $416,893,000 after purchasing an additional 263,105 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Laboratory Co. of America by 135.0% during the second quarter. Bank of New York Mellon Corp now owns 1,609,826 shares of the medical research company's stock worth $327,616,000 after purchasing an additional 924,881 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Laboratory Co. of America by 2.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,417,645 shares of the medical research company's stock worth $288,519,000 after purchasing an additional 33,497 shares in the last quarter. Finally, Cooke & Bieler LP boosted its position in shares of Laboratory Co. of America by 26.8% in the 2nd quarter. Cooke & Bieler LP now owns 928,250 shares of the medical research company's stock worth $188,908,000 after buying an additional 196,119 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

Insider Activity at Laboratory Co. of America

In other news, CEO Adam H. Schechter sold 6,189 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the completion of the transaction, the chief executive officer now owns 87,441 shares of the company's stock, valued at approximately $21,289,260.27. The trade was a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the director now directly owns 13,722 shares in the company, valued at approximately $3,156,060. This trade represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LH shares. Robert W. Baird boosted their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Bank of America upped their target price on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a "buy" rating in a report on Monday, August 5th. Barclays lifted their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an "equal weight" rating in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Laboratory Co. of America from $220.00 to $230.00 and gave the stock a "hold" rating in a research report on Friday, August 2nd. Finally, UBS Group increased their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Laboratory Co. of America presently has an average rating of "Moderate Buy" and an average target price of $255.92.

Laboratory Co. of America Stock Performance

Shares of LH stock opened at $237.85 on Thursday. The company's fifty day moving average price is $225.35 and its two-hundred day moving average price is $216.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a market capitalization of $19.89 billion, a P/E ratio of 46.01, a P/E/G ratio of 1.94 and a beta of 1.05. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $247.99.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. The firm had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. During the same quarter in the prior year, the business posted $3.38 earnings per share. Laboratory Co. of America's revenue for the quarter was up 7.4% on a year-over-year basis. On average, research analysts anticipate that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.21%. Laboratory Co. of America's dividend payout ratio (DPR) is 55.71%.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.